期刊文献+

液相色谱-串联质谱法以锂加合离子定量分析大鼠血浆中紫杉醇和羟基代谢物 被引量:4

Determination of Paclitaxel and Hydroxylated Metabolites in Rat Plasma with Lithium Adduct Ion by LC-MS/MS
下载PDF
导出
摘要 为了提高大鼠血浆中紫杉醇和羟基代谢物的检测灵敏度,本工作探索了加入金属离子的液相色谱-串联质谱联用方法。紫杉醇质谱分析时,易产生碱金属(Li+、Na+、K+)加合离子。采用未添加碱金属离子的流动相分析时,[M+H]+质谱响应低,[M+Na]+稳定性差。本实验以碳酸锂作为试剂,同时定量测定大鼠血浆中紫杉醇和羟基代谢物,紫杉醇的线性范围为1.00~8 000μg/L,3’-p-羟基紫杉醇的线性范围为0.50~50μg/L。本方法专属性好,准确、快速,适用于注射用紫杉醇(白蛋白结合型)的药代动力学研究。锂加合离子稳定性好、质谱响应高、碰撞能量低,适用于一些中性化合物的定量和结构分析。 A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was explored for improving the sensitivity of paclitaxel and 3'-p-hydroxypaclitaxel in rat plasma with metal ion. Paclitaxel is easy to produce alkali metal adduct ions (Li+ , Na+ , K+ ) dur- ing mass spectrometry analysis. The mass spectrometry response of [M+ HI+ is low and the stability of [M+Na]+ is poor without adding metal ions in the mobile phase. In this study, paclitaxel and hydroxylated metabolites were quantative analyzed using lithium car- bonate reagent. The linear concentration ranges of the calibration curves for paclitaxel and 3 '-p-hydroxypaclitaxel are 1.00--8 000 μg/L and 0.50--50 μg/L, respectively. The meth- od is sensitive, simple and rapid, which is suitable for the pharmacokinetic study of the al- bumin-bound (nab-)paclitaxel. Lithium adduct ion is stable, high mass spectrometryresponse and low collision energy, is suitable for the quantative and structural analysis of some neutral compounds.
出处 《质谱学报》 EI CAS CSCD 北大核心 2013年第3期137-144,共8页 Journal of Chinese Mass Spectrometry Society
关键词 锂加合离子 紫杉醇 羟基代谢物 液相色谱-串联质谱 lithium adduct ion paclitaxel hydroxylated metabolites liquid chromatogra-phy-tandem mass spectrometry
  • 相关文献

参考文献20

  • 1FERLINI C, OJIMA I, DISTEFANO M, et al. Second generation taxanes: From the natural framework to the challenge of drug resistance[J]. Curr Med Chem Anti-Cancer Agents, 2003, 3: 133-138.
  • 2MIELE E, SPPINELLI G P, MIELE E, et al. Albumin-bound formulation of paclitaxel (Ahrax- ane ABI-007) in the treatment of breast cancer [J]. Int J Nanomedicine, 2009, (4): 99-105.
  • 3GARDERN E R, DAHUT W L, SCRIPTURE C D. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel [J]. Clin Cancer Res, 2008, 14(13): 4 199-4 205.
  • 4GRADISHAR W J. Albumin-bound paclitaxel: A next-generation taxane[J]. Expert Opin Pharma- cother, 2006, 7(8): 1 041-1 053.
  • 5JAMIS-DOW C A, KLECKER R W, KATKI AG, et al. Metabolism of taxol by human and rat liver in vitro., a screen for drug interactions and inter- species differences[J]. Cancer Chemother Pharma- col, 1995, 36: 107-114.
  • 6ANDERSON C D, WANG J, KUMAR G N, et al. Dexamethason induction of taxol metabolism in the rat[J]. Drug Metab Dispos, 1995, 23: 1 286-1 290.
  • 7MONSARRAT B, MARIEL E, Cros S, et al. T- axol metabolism isolation and identification of three major metabolites of taxol in rat bile [J]. Drug Metab Dispos, 1990, 18(6): 895-901.
  • 8ARORA V. Antisense strategies for redirection of drug metabolism:Using paclitaxel as a model[J]. Methods Mol Med, 2004, 106: 273-292.
  • 9SPRATLIN J, SAWYER M B. Pharmacogenetics of paclitaxel metabolism[J]. Crit Rev Oncol/He- matol, 2007, 61: 222-229.
  • 10CECH N B, ENKE C G. Practical implications of some recent studies in electrospray ionization fundamentals[J]. Mass Spectrom Rev, 2001, 20: 362-387.

同被引文献34

  • 1CFDA(国家食品药品管理局).Good Laboratory Practice for Nonclinical Laboratory Studies(药物非临床研究质量管理规范)[S].2003.
  • 2JEMAL M. High throughput quantitative bioanalysis by LC-MS/ MS [J]. Biomed Chromatogr, 2000, 14(6) :422-429.
  • 3XU R N, FAN L, RIESER M J, et al. Recent advances in high- throughput quantitative bioanalysis by LC-klS/MS[ J]. J Pharm Biomed Anal,2007,44(2) :342-355.
  • 4KORFMARCHER W A. Principles and applications of LC-MS in new drug discovery [ J ]. Drug Discov Today, 2005, 10 ( 20 ) : 1357-1367.
  • 5CARTER G D. 25-Hydroxyvitamin D assays: The quest for accu- racy[J]. Clin Chem,2009 ,55 ( 7 ) :1300-1302.
  • 6SINGH R J. Are clinical laboratories prepared for accurate testing of 25-hydroxy vitamin D [ J ]. Clin Chem ,2008,54 ( 1 ) :221-223.
  • 7ZHOU M. Regulated Bioanalytical Laboratories: Technical and Regulatory Aspects from Global Perspectives [ M ]. New Jersey : Wi- ley, 2011 : 12-59 ;558-568.
  • 8WEI M J, ZHANG Y H, ZHANG Z F. Accuracy problems during the analysis of biosamples and discussions on the improving meas- ures. [ DB/OL]. [2012-04-11 ]. http://www, cde. org. cn/dz- kw. do? method = largePage&id = 312642.
  • 9CFDA. Guideline on the Human Bioavailability and Bioequiva- lence of Chemical Drug Preparations(化学药物制剂人体生物利用度和生物等效性研究技术指导原则)[S].2005.
  • 10KORFMACHER W A. Mass Spectrometry for Drug Discovery and Drug Development[ M]. New Jersey: Wiley, 2013:55-95.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部